Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02081638 · ClinicalTrials.gov registry record · Phase 2
Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study
A Phase 2 study of Human Immunodeficiency Virus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 2
- Study locations
NCT02081638: Completed Phase 2 study of Human Immunodeficiency Virus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02081638 is a Phase 2 study of Human Immunodeficiency Virus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 53 participants, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02081638, a Phase 2 study of Human Immunodeficiency Virus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- The immune system protects the body from infection. But it can also cause harm. For example, the clotting system makes blood clot and protects from bleeding. But blood clots are sometimes harmful. People with human immunodeficiency virus (HIV) infection have increased inflammation and clotting. This may increase their risk for diseases like stroke or heart attack. Researchers want to know how aspirin or HMG-CoA reductase inhibitors (so-called statin medications) affect the immune and clotting systems of people with HIV. Aspirin is a medicine to decrease clotting. Statins are medications given to lower cholesterol and decrease inflammation. Objectives: \- To see how aspirin or statins change immune and clotting systems in people with HIV. Eligibility: \- Adults 18 and older with HIV and a low viral load, not on aspirin or a statin medication. They must also have either: (1) never taken anti-HIV medications (ARVs), have a suppressed viral load, have stable CD4 counts, and never had an opportunistic infection; or (2) been taking ARVs for 5 continuous years and have a suppressed viral load for more than 3 years. Design: * Participants will be screened with medical history, physical exam, and blood and lab tests. * Participants will repeat screening tests and have an MRI. An MRI is a way to visualize blood vessels in the neck and head. Participants will lie on a table that slides in and out of a cylinder surrounded by a magnetic field. * Participants will take either study drug once daily for 9 months. * Participants will have a blood procedure twice. Blood will be removed through a needle in one arm and circulated through a machine that removes white blood cells. The blood, minus white blood cells, is returned through a needle in the other arm. * All participants will be observed for 3 months before and after treatment.
Primary Outcome
sCD14 change between baseline (average of month 0 and month 3 in the study) and month 12
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Atorvastatin
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Minnesota
- Hennipen County Medical Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-04-18 |
| Est. Completion | 2019-10-16 |
| Phase | Phase 2 |
What the finished NCT02081638 record still lists
NCT02081638 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT02081638 reports a single indexed study location in Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02081638 about?
NCT02081638 is a clinical study titled "Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study". Background: \- The immune system protects the body from infection. But it can also cause harm. For example, the clotting system makes blood clot and protects from bleeding. But blood clots are sometimes harmful. People with human immunodeficiency virus (HIV) infection have increased inflammation an...
What is the current status of trial NCT02081638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2014-04-18. Estimated completion is 2019-10-16.
What conditions does trial NCT02081638 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT02081638?
The interventions under investigation include: Aspirin (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT02081638?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02081638 being conducted?
This trial has 2 study locations across Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02081638's enrollment target sits among peer trials
53 22nd of 39 higher than 18 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI